Immunotherapy for rapid bone marrow conditioning and leukemia depletion that allows efficient hematopoietic stem cell transplantation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F25%3A00642439" target="_blank" >RIV/68378050:_____/25:00642439 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/25:10499306
Result on the web
<a href="https://doi.org/10.1136/jitc-2025-011888" target="_blank" >https://doi.org/10.1136/jitc-2025-011888</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/jitc-2025-011888" target="_blank" >10.1136/jitc-2025-011888</a>
Alternative languages
Result language
angličtina
Original language name
Immunotherapy for rapid bone marrow conditioning and leukemia depletion that allows efficient hematopoietic stem cell transplantation
Original language description
Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure to treat hematopoietic disorders. Current bone marrow conditioning protocols create space for healthy donor stem cells by employing irradiation and/or chemotherapy, but carry severe toxicities, resulting in significant morbidity, mortality and substantial long-term complications. To develop a low-toxicity solution, we generated a bi-specific T-cell engager (BTCE) that targets CD117, an abundantly expressed receptor on hematopoietic stem and progenitor cells (HSPC) and leukemia-initiating cells (LICs). We show that the CD117xCD3 BTCE efficiently depletes in vitro and in vivo HSPCs and LICs. The CD117xCD3 BTCE was not toxic and facilitates highly efficient engraftment of human allogenic donor CD34+cells in humanized mice, thereby restoring hematopoiesis in vivo in both normal and leukemia-bearing humanized mice. We demonstrate here that a potent CD117xCD3 BTCE enables rapid HSCT in both benign and malignant conditions.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal for ImmunoTherapy of Cancer
ISSN
2051-1426
e-ISSN
2051-1426
Volume of the periodical
13
Issue of the periodical within the volume
6
Country of publishing house
GB - UNITED KINGDOM
Number of pages
13
Pages from-to
e011888
UT code for WoS article
001519647600001
EID of the result in the Scopus database
2-s2.0-105009640028